TARO - Taro Pharmaceutical Industries Ltd.

NYSE - NYSE Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue879,387950,751862,944
Cost of Revenue208,136171,785186,359
Gross Profit671,251778,966676,585
Operating Expenses
Research Development70,64471,16065,510
Selling General and Administrative85,65693,33883,444
Non Recurring---
Total Operating Expenses---
Operating Income or Loss514,951614,468527,631
Income from Continuing Operations
Total Other Income/Expenses Net45,84722,35254,049
Earnings Before Interest and Taxes560,798636,820581,680
Interest Expense---
Income Before Tax560,798636,820581,680
Income Tax Expense103,78095,31396,059
Minority Interest6,3126,0025,663
Net Income From Continuing Ops457,018541,507485,621
Non-recurring Events
Discontinued Operations-352-236-787
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income456,356540,932484,257
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares456,356540,932484,257